| Effect of recombinant human erythropoietin and intravenous iron on anemia and disease activity in rheumatoid arthritis. | |
| | |
MedLine Citation:
|
PMID: 11708414 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To investigate whether treatment of anemia of chronic disease (ACD) in patients with rheumatoid arthritis (RA) with recombinant human erythropoietin (rHu-Epo) in combination with intravenous (i.v.) iron influences health related quality of life (HRQoL) and clinical outcome including disease activity. METHODS: Thirty patients with ACD and RA were treated with 150 IU/kg rHu-Epo twice weekly for 12 weeks. As well, in case of functional iron deficiency 200 mg of iron-sucrose per week was given intravenously. Vitality and fatigue as dimensions of HRQoL were evaluated by the vitality subscale of the Short Form-36 (SF-36-VT) and the Multidimensional Assessment of Fatigue (MAF). Muscle strength was measured by the Muscle Strength Index. RESULTS: All 28 patients completing the study responded to treatment; 23/28 patients developed functional iron deficiency and received i.v. iron (mean absolute dose 710 +/- 560 mg). Average hemoglobin concentration increased from 10.7 +/- 1.1 to 13.2 +/- 1.0 g/dl after a mean treatment period of 8.7 +/- 2.3 weeks. Muscle strength increased from 43.5 +/- 11.2 to 49.1 +/- 12.9 and SF-36-VT from 28.2% +/- 14.3% to 47.1% +/- 20.8%. while fatigue decreased (MAF from 34.7 +/- 9.3 to 25.0 +/- 11.3). Among the disease activity variables the number of swollen/tender joints, erythrocyte sedimentation rate, Disease Activity Score, and RA Disease Activity Index improved significantly during treatment. CONCLUSION: Treatment of ACD in RA patients with rHu-Epo and i.v. iron is safe and effective in correction of anemia, increases muscle strength. improves vitality, and lowers fatigue. In addition we observed a reduction of disease activity. |
| | |
Authors:
|
J P Kaltwasser; U Kessler; R Gottschalk; G Stucki; B Möller |
Related Documents
:
|
8017744 - The anemia of primary autonomic failure and its reversal with recombinant erythropoietin. 18679684 - Patients with iron deficiency anemia have an increased prevalence of gallstones. 1588794 - Recombinant human erythropoietin for treatment of myelodysplastic syndromes. 21494624 - High frequency of chronic bacterial and non-inflammatory prostatitis in infertile patie... 8192534 - The effect of subcutaneous recombinant human erythropoietin (r-hu epo) in capd patients... 19811814 - Regional changes in word-production laterality after a naming treatment designed to pro... |
Publication Detail:
|
Type: Clinical Trial; Journal Article |
Journal Detail:
|
Title: The Journal of rheumatology Volume: 28 ISSN: 0315-162X ISO Abbreviation: J. Rheumatol. Publication Date: 2001 Nov |
Date Detail:
|
Created Date: 2001-11-15 Completed Date: 2002-04-04 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 7501984 Medline TA: J Rheumatol Country: Canada |
Other Details:
|
Languages: eng Pagination: 2430-6 Citation Subset: IM |
Affiliation:
|
Medizinische Klinik III, Bereich Rheumatologie, J.W. Goethe-Universität, Frankfurt/Main, Germany. Kaltwasser@em.Uni-frankfurt.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Anemia / drug therapy*, etiology Arthritis, Rheumatoid / complications, drug therapy*, physiopathology Disability Evaluation Erythropoietin, Recombinant / administration & dosage, therapeutic use* Female Ferric Compounds / administration & dosage, therapeutic use* Health Status Humans Injections, Intravenous Injections, Subcutaneous Male Middle Aged Quality of Life Severity of Illness Index Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Erythropoietin, Recombinant; 0/Ferric Compounds; 8047-67-4/ferric oxide, saccharated |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: High mortality in patients with rheumatoid arthritis and atlantoaxial subluxation.
Next Document: Antiphospholipid antibodies: a risk factor for occlusive retinal vascular disorders. Comparison with...